Results 21 to 30 of about 10,630 (206)
The current toolbox for APOBEC drug discovery [PDF]
Trends in Pharmacological Sciences, 2022 Mutational processes driving genome evolution and heterogeneity contribute to immune evasion and therapy resistance in viral infections and cancer. APOBEC3 (A3) enzymes promote such mutations by catalyzing the deamination of cytosines to uracils in single-stranded DNA.
Michael J. Grillo +4 more
openaire +2 more sources
AID/APOBEC deaminases and cancer [PDF]
Oncoscience, 2015 Mutations are the basis for evolution and the development of genetic diseases. Especially in cancer, somatic mutations in oncogenes and tumor suppressor genes alongside the occurrence of passenger mutations have been observed by recent deep-sequencing approaches.
Stefan, Rebhandl +3 more
openaire +2 more sources
APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses [PDF]
, 2022 The APOBEC family of cytidine deaminases is one of the most common endogenous sources of mutations in human cancer. Genomic studies of tumors have found that APOBEC mutational signatures are enriched in theHER2 subtype of breast cancer and are associated
Xie, J +11 more
core +1 more source
Special Issue “APOBECs and Virus Restriction” [PDF]
Viruses, 2021 The apolipoprotein B mRNA editing enzyme, catalytic polypeptide (APOBEC) enzyme family in humans has 11 members with diverse functions in metabolism and immunity [...]
openaire +3 more sources
Virology, 2015 The APOBEC family of single-stranded DNA cytosine deaminases comprises a formidable arm of the vertebrate innate immune system. Pre-vertebrates express a single APOBEC, whereas some mammals produce as many as 11 enzymes. The APOBEC3 subfamily displays both copy number variation and polymorphisms, consistent with ongoing pathogenic pressures.
Harris, Reuben S., Dudley, Jaquelin P.
openaire +2 more sources
APOBEC3A is a prominent cytidine deaminase in breast cancer.
PLoS Genetics, 2019 APOBEC cytidine deaminases are the second-most prominent source of mutagenesis in sequenced tumors. Previous studies have proposed that APOBEC3B (A3B) is the major source of mutagenesis in breast cancer (BRCA).
Luis M Cortez +7 more
doaj +1 more source
APOBEC‐mediated interference with hepadnavirus production† [PDF]
Hepatology, 2005 APOBEC3G is a cellular cytidine deaminase displaying broad antiretroviral activity. Recently, it was shown that APOBEC3G can also suppress hepatitis B virus (HBV) production in human hepatoma cells. In the present study, we characterized the mechanisms of APOBEC-mediated antiviral activity against HBV and related hepadnaviruses.
Rosler, C +6 more
openaire +3 more sources
Journal of Lipid Research, 1997 ApolipoproteinB (apoB) mRNA editing involves a C to U deamination of the nuclear apoB mRNA and occurs in mammalian small intestine and in the liver of certain species. This reaction is mediated by a multicomponent enzyme complex that includes a catalytic
K Hirano +3 more
doaj +1 more source
OncoImmunology, 2017 Immunotherapy with checkpoint inhibitors, such as antibodies blocking the programmed cell-death receptor-1 (PD-1), has resulted in remarkable responses in patients having traditionally refractory cancers.
Amélie Boichard +2 more
doaj +1 more source
Hypermutation of ApoB mRNA by Rat APOBEC-1 Overexpression Mimics APOBEC-3 Hypermutation [PDF]
Journal of Molecular Biology, 2012 APOBEC-3 proteins induce C-to-U hypermutations in the viral genome of various viruses and have broad antiviral activity. Generally, only a small proportion of viral genomes (
Zhigang, Chen +7 more
openaire +2 more sources